Skip to main content
Erschienen in: Tumor Biology 1/2013

01.02.2013 | Research Article

ILK and PRDX1 are prognostic markers in squamous cell/adenosquamous carcinomas and adenocarcinoma of gallbladder

verfasst von: Jinghe Li, Zhu-lin Yang, Xuebao Ren, Qiong Zou, Yuan Yuan, Lufeng Liang, Meigui Chen, Senlin Chen

Erschienen in: Tumor Biology | Ausgabe 1/2013

Einloggen, um Zugang zu erhalten

Abstract

Although the incidence of gallbladder cancers is low, they are highly aggressive tumors. Squamous cell/adenosquamous carcinoma (SC/ASC) is a rare subtype of gallbladder cancer. The clinical characteristics of SC/ASC have not been well documented, and no prognosis marker has been identified. In this study, we examined integrin-linked kinase (ILK) and peroxiredoxin-1 (PRDX1) expression in 46 SC/ASCs and 80 adenocarcinomas (ACs) by using immunohistochemistry and analyzed their correlations with clinicopathological characteristics. We demonstrated that positive ILK and PRDX1 expressions were significantly associated with large tumor size, high TNM stage, lymph node metastasis, and invasion of SC/ASC and AC. Univariate Kaplan–Meier analysis showed that positive ILK and PRDX1 expressions were closely associated with decreased overall survival in both SC/ASC (p < 0.001 and p = 0.005, respectively) and AC (p < 0.001) patients. Multivariate Cox regression analysis showed that positive ILK and PRDX1 expressions were an independent poor prognostic predictor in both SC/ASC and AC patients. We also revealed a similar significance of differentiation, tumor size, TNM stage, lymph node metastasis, invasion, and surgical curability with survival in SC/ASC and AC patients. Our study suggested that positive ILK and PRDX1 expressions are closely related to the progression and poor prognosis of gallbladder cancer.
Literatur
1.
Zurück zum Zitat Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71–96.PubMedCrossRef Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71–96.PubMedCrossRef
2.
Zurück zum Zitat Jayaraman S, Jarnagin WR. Management of gallbladder cancer. Gastroenterol Clin N Am. 2010;39:331–42.CrossRef Jayaraman S, Jarnagin WR. Management of gallbladder cancer. Gastroenterol Clin N Am. 2010;39:331–42.CrossRef
3.
Zurück zum Zitat Ootani T, Shirai Y, Tsukada K, Muto T. Relationship between gallbladder carcinoma and the segmental type of adenomyomatosis of the gallbladder. Cancer. 1992;69:2647–52.PubMedCrossRef Ootani T, Shirai Y, Tsukada K, Muto T. Relationship between gallbladder carcinoma and the segmental type of adenomyomatosis of the gallbladder. Cancer. 1992;69:2647–52.PubMedCrossRef
4.
Zurück zum Zitat Roa JC, Tapia O, Cakir A, Basturk O, Dursun N, Akdemir D, et al. Squamous cell and adenosquamous carcinomas of the gallbladder: clinicopathological analysis of 34 cases identified in 606 carcinomas. Mod Pathol. 2011;24:1069–78.PubMedCrossRef Roa JC, Tapia O, Cakir A, Basturk O, Dursun N, Akdemir D, et al. Squamous cell and adenosquamous carcinomas of the gallbladder: clinicopathological analysis of 34 cases identified in 606 carcinomas. Mod Pathol. 2011;24:1069–78.PubMedCrossRef
5.
Zurück zum Zitat Reid KM, Ramos-De la Medina A, Donohue JH. Diagnosis and surgical management of gallbladder cancer: a review. J Gastrointest Surg. 2007;11:671–81.PubMedCrossRef Reid KM, Ramos-De la Medina A, Donohue JH. Diagnosis and surgical management of gallbladder cancer: a review. J Gastrointest Surg. 2007;11:671–81.PubMedCrossRef
6.
Zurück zum Zitat de Aretxabala X, Roa I, Burgos L, et al. Gallbladder cancer: an analysis of a series of 139 patients with restricted to the subserosal layer. J Gastrointest Surg. 2006;10:186–92.PubMedCrossRef de Aretxabala X, Roa I, Burgos L, et al. Gallbladder cancer: an analysis of a series of 139 patients with restricted to the subserosal layer. J Gastrointest Surg. 2006;10:186–92.PubMedCrossRef
7.
Zurück zum Zitat Hawkins WG, DeMatteo RP, Jarnagin WR, Ben-Porat L, Blumgart LH, Fong Y. Jaundice predicts advanced disease and early mortality in patients with gallbladder cancer. Ann Surg Oncol. 2004;11:310–5.PubMedCrossRef Hawkins WG, DeMatteo RP, Jarnagin WR, Ben-Porat L, Blumgart LH, Fong Y. Jaundice predicts advanced disease and early mortality in patients with gallbladder cancer. Ann Surg Oncol. 2004;11:310–5.PubMedCrossRef
8.
Zurück zum Zitat Durbin AD, Hannigan GE, Malkin D. Oncogenic ILK, tumor suppression and all that JNK. Cell Cycle. 2009;8:4060–6.PubMedCrossRef Durbin AD, Hannigan GE, Malkin D. Oncogenic ILK, tumor suppression and all that JNK. Cell Cycle. 2009;8:4060–6.PubMedCrossRef
9.
Zurück zum Zitat McDonald PC, Fielding AB, Dedhar S. Integrin-linked kinase—essential roles in physiology and cancer biology. J Cell Sci. 2008;121:3121–32.PubMedCrossRef McDonald PC, Fielding AB, Dedhar S. Integrin-linked kinase—essential roles in physiology and cancer biology. J Cell Sci. 2008;121:3121–32.PubMedCrossRef
10.
Zurück zum Zitat Cortez V, Nair BC, Chakravarty D, Vadlamudi RK. Integrin-linked kinase 1: role in hormonal cancer progression. Front Biosci (Schol Ed). 2011;3:788–96.CrossRef Cortez V, Nair BC, Chakravarty D, Vadlamudi RK. Integrin-linked kinase 1: role in hormonal cancer progression. Front Biosci (Schol Ed). 2011;3:788–96.CrossRef
11.
Zurück zum Zitat Watzka SB, Rauscher-Pötsch I, Stubenberger E, Getman V, Setinek U, Tötsch M, et al. Immunoreactivity of integrin-linked kinase in primary non-small-cell lung cancer and survival after curative resection. Eur J Cardiothorac Surg. 2010;38:254–9.PubMedCrossRef Watzka SB, Rauscher-Pötsch I, Stubenberger E, Getman V, Setinek U, Tötsch M, et al. Immunoreactivity of integrin-linked kinase in primary non-small-cell lung cancer and survival after curative resection. Eur J Cardiothorac Surg. 2010;38:254–9.PubMedCrossRef
12.
Zurück zum Zitat Sawai H, Okada Y, Funahashi H, Matsuo Y, Takahashi H, Takeyama H, et al. Integrin-linked kinase activity is associated with interleukin-1 alpha-induced progressive behavior of pancreatic cancer and poor patient survival. Oncogene. 2006;25:3237–46.PubMedCrossRef Sawai H, Okada Y, Funahashi H, Matsuo Y, Takahashi H, Takeyama H, et al. Integrin-linked kinase activity is associated with interleukin-1 alpha-induced progressive behavior of pancreatic cancer and poor patient survival. Oncogene. 2006;25:3237–46.PubMedCrossRef
13.
Zurück zum Zitat Intaraprasong P, Assi K, Owen DA, Huntsman DG, Chung SW, Scudamore CH, et al. Expression of integrin-linked kinase is not a useful prognostic marker in resected hepatocellular cancer. Anticancer Res. 2007;27:4371–6.PubMed Intaraprasong P, Assi K, Owen DA, Huntsman DG, Chung SW, Scudamore CH, et al. Expression of integrin-linked kinase is not a useful prognostic marker in resected hepatocellular cancer. Anticancer Res. 2007;27:4371–6.PubMed
14.
Zurück zum Zitat Maxwell GL, Hood BL, Day R, Chandran U, Kirchner D, Kolli VS, et al. Proteomic analysis of stage I endometrial cancer tissue: identification of proteins associated with oxidative processes and inflammation. Gynecol Oncol. 2011;121:586–94.PubMedCrossRef Maxwell GL, Hood BL, Day R, Chandran U, Kirchner D, Kolli VS, et al. Proteomic analysis of stage I endometrial cancer tissue: identification of proteins associated with oxidative processes and inflammation. Gynecol Oncol. 2011;121:586–94.PubMedCrossRef
15.
Zurück zum Zitat Hoshino I, Matsubara H, Akutsu Y, Nishimori T, Yoneyama Y, Murakami K, et al. Tumor suppressor Prdx1 is a prognostic factor in esophageal squamous cell carcinoma patients. Oncol Rep. 2007;18:867–71.PubMed Hoshino I, Matsubara H, Akutsu Y, Nishimori T, Yoneyama Y, Murakami K, et al. Tumor suppressor Prdx1 is a prognostic factor in esophageal squamous cell carcinoma patients. Oncol Rep. 2007;18:867–71.PubMed
16.
Zurück zum Zitat Neumann AC, Fang Q. Are peroxiredoxins tumor suppressors? Curr Opin Pharmacol. 2007;7:375–80.PubMedCrossRef Neumann AC, Fang Q. Are peroxiredoxins tumor suppressors? Curr Opin Pharmacol. 2007;7:375–80.PubMedCrossRef
17.
Zurück zum Zitat Wen ST, Van Etten RA. The PAG gene product, a stress-induced protein with antioxidant properties, is an Abl SH3-binding protein and a physiological inhibitor of c-Abl tyrosine kinase activity. Genes Dev. 1997;11:2456–67.PubMedCrossRef Wen ST, Van Etten RA. The PAG gene product, a stress-induced protein with antioxidant properties, is an Abl SH3-binding protein and a physiological inhibitor of c-Abl tyrosine kinase activity. Genes Dev. 1997;11:2456–67.PubMedCrossRef
18.
Zurück zum Zitat Mu ZM, Yin XY, Prochownik EV. Pag, a putative tumor suppressor, interacts with the Myc Box II domain of c-Myc and selectively alters its biological function and target gene expression. J Biol Chem. 2002;277:43175–84.PubMedCrossRef Mu ZM, Yin XY, Prochownik EV. Pag, a putative tumor suppressor, interacts with the Myc Box II domain of c-Myc and selectively alters its biological function and target gene expression. J Biol Chem. 2002;277:43175–84.PubMedCrossRef
19.
Zurück zum Zitat Yanagawa T, Iwasa S, Ishii T, et al. Peroxiredoxin I expression in oral cancer: a potential new tumor marker. Cancer Lett. 2000;156:27–35.PubMedCrossRef Yanagawa T, Iwasa S, Ishii T, et al. Peroxiredoxin I expression in oral cancer: a potential new tumor marker. Cancer Lett. 2000;156:27–35.PubMedCrossRef
20.
Zurück zum Zitat Quan C, Cha EJ, Lee HL, Han KH, Lee KM, Kim WJ. Enhanced expression of peroxiredoxin I and VI correlates with development, recurrence and progression of human bladder cancer. J Urol. 2006;175:1512–6.PubMedCrossRef Quan C, Cha EJ, Lee HL, Han KH, Lee KM, Kim WJ. Enhanced expression of peroxiredoxin I and VI correlates with development, recurrence and progression of human bladder cancer. J Urol. 2006;175:1512–6.PubMedCrossRef
21.
Zurück zum Zitat Chung KH, Lee DH, Kim Y, Kim TH, Huh JH, Chung SG, et al. Proteomic identification of overexpressed PRDX 1 and its clinical implications in ovarian carcinoma. J Proteome Res. 2010;9:451–7.PubMedCrossRef Chung KH, Lee DH, Kim Y, Kim TH, Huh JH, Chung SG, et al. Proteomic identification of overexpressed PRDX 1 and its clinical implications in ovarian carcinoma. J Proteome Res. 2010;9:451–7.PubMedCrossRef
22.
Zurück zum Zitat Kim JH, Bogner PN, Baek SH, Ramnath N, Liang P, Kim HR, et al. Up-regulation of peroxiredoxin 1 in lung cancer and its implication as a prognostic and therapeutic target. Clin Cancer Res. 2008;14:2326–33.PubMedCrossRef Kim JH, Bogner PN, Baek SH, Ramnath N, Liang P, Kim HR, et al. Up-regulation of peroxiredoxin 1 in lung cancer and its implication as a prognostic and therapeutic target. Clin Cancer Res. 2008;14:2326–33.PubMedCrossRef
23.
Zurück zum Zitat Hoshino I, Matsubara H, Akutsu Y, Nishimori T, Yoneyama Y, Murakami K, et al. Tumor suppressor Prdx1 is a prognostic factor in esophageal squamous cell carcinoma patients. Oncol Rep. 2007;18:867–71.PubMed Hoshino I, Matsubara H, Akutsu Y, Nishimori T, Yoneyama Y, Murakami K, et al. Tumor suppressor Prdx1 is a prognostic factor in esophageal squamous cell carcinoma patients. Oncol Rep. 2007;18:867–71.PubMed
24.
Zurück zum Zitat Liu DC, Yang ZL, Jiang S. Identification of musashi-1 and ALDH1 as carcinogenesis, progression, and poor-prognosis related biomarkers for gallbladder adenocarcinoma. Cancer Biomark. 2010–2011;8:113–21. Liu DC, Yang ZL, Jiang S. Identification of musashi-1 and ALDH1 as carcinogenesis, progression, and poor-prognosis related biomarkers for gallbladder adenocarcinoma. Cancer Biomark. 2010–2011;8:113–21.
25.
Zurück zum Zitat Nishihara K, Nagai E, Izumi Y, et al. Adenosquamous carcinoma of the gallbladder: a clinicopathological, immunohistochemical and flow-cytometric study of twenty cases. Jpn J Cancer Res. 1994;85:389–99.PubMedCrossRef Nishihara K, Nagai E, Izumi Y, et al. Adenosquamous carcinoma of the gallbladder: a clinicopathological, immunohistochemical and flow-cytometric study of twenty cases. Jpn J Cancer Res. 1994;85:389–99.PubMedCrossRef
26.
Zurück zum Zitat Kondo M, Dono K, Sakon M, et al. Adenosquamous carcinoma of the gallbladder. Hepatogastroenterology. 2002;49:1230–4.PubMed Kondo M, Dono K, Sakon M, et al. Adenosquamous carcinoma of the gallbladder. Hepatogastroenterology. 2002;49:1230–4.PubMed
27.
Zurück zum Zitat Cortez V, Nair BC, Chakravarty D, Vadlamudi RK. Integrin-linked kinase 1: role in hormonal cancer progression. Front Biosci (Schol Ed). 2011;3:788–96.CrossRef Cortez V, Nair BC, Chakravarty D, Vadlamudi RK. Integrin-linked kinase 1: role in hormonal cancer progression. Front Biosci (Schol Ed). 2011;3:788–96.CrossRef
28.
Zurück zum Zitat Graff JR, Deddens JA, Konicek BW, Colligan BM, Hurst BM, Carter HW, et al. Integrin-linked kinase expression increases with prostate tumor grade. Clin Cancer Res. 2001;7:1987–91.PubMed Graff JR, Deddens JA, Konicek BW, Colligan BM, Hurst BM, Carter HW, et al. Integrin-linked kinase expression increases with prostate tumor grade. Clin Cancer Res. 2001;7:1987–91.PubMed
29.
Zurück zum Zitat Prosperi MT, Ferbus D, Karczinski I, Goubin G. A human cDNA corresponding to a gene overexpressed during cell proliferation encodes a product sharing homology with amoebic and bacterial proteins. J Biol Chem. 1993;268:11050–6.PubMed Prosperi MT, Ferbus D, Karczinski I, Goubin G. A human cDNA corresponding to a gene overexpressed during cell proliferation encodes a product sharing homology with amoebic and bacterial proteins. J Biol Chem. 1993;268:11050–6.PubMed
Metadaten
Titel
ILK and PRDX1 are prognostic markers in squamous cell/adenosquamous carcinomas and adenocarcinoma of gallbladder
verfasst von
Jinghe Li
Zhu-lin Yang
Xuebao Ren
Qiong Zou
Yuan Yuan
Lufeng Liang
Meigui Chen
Senlin Chen
Publikationsdatum
01.02.2013
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 1/2013
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-012-0557-2

Weitere Artikel der Ausgabe 1/2013

Tumor Biology 1/2013 Zur Ausgabe

Blutdrucksenkung könnte Uterusmyome verhindern

Frauen mit unbehandelter oder neu auftretender Hypertonie haben ein deutlich erhöhtes Risiko für Uterusmyome. Eine Therapie mit Antihypertensiva geht hingegen mit einer verringerten Inzidenz der gutartigen Tumoren einher.

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

16.05.2024 Zielgerichtete Therapie Nachrichten

Trastuzumab deruxtecan scheint auch jenseits von Lungenkrebs gut gegen solide Tumoren mit HER2-Mutationen zu wirken. Dafür sprechen die Daten einer offenen Pan-Tumor-Studie.

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

15.05.2024 Mammakarzinom Nachrichten

Frauen mit lokalem oder metastasiertem Brustkrebs, die Statine einnehmen, haben eine niedrigere krebsspezifische Mortalität als Patientinnen, die dies nicht tun, legen neue Daten aus den USA nahe.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.